These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 16269617)
1. Survival of the fittest: in vivo selection and stem cell gene therapy. Neff T; Beard BC; Kiem HP Blood; 2006 Mar; 107(5):1751-60. PubMed ID: 16269617 [TBL] [Abstract][Full Text] [Related]
2. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning. Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699 [TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cell transduction and amplification in large animal models. Trobridge G; Beard BC; Kiem HP Hum Gene Ther; 2005 Dec; 16(12):1355-66. PubMed ID: 16390267 [TBL] [Abstract][Full Text] [Related]
4. Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency. Trobridge GD; Beard BC; Wu RA; Ironside C; Malik P; Kiem HP PLoS One; 2012; 7(9):e45173. PubMed ID: 23028826 [TBL] [Abstract][Full Text] [Related]
6. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice. Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446 [TBL] [Abstract][Full Text] [Related]
7. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments]. Smogorzewska EM; Weinberg KI; Kohn DB Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167 [TBL] [Abstract][Full Text] [Related]
8. Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety. Cicalese MP; Ferrua F; Castagnaro L; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Roncarolo MG; Aiuti A Mol Ther; 2018 Mar; 26(3):917-931. PubMed ID: 29433935 [TBL] [Abstract][Full Text] [Related]
9. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies. Silver JN; Flotte TR Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656 [TBL] [Abstract][Full Text] [Related]
10. Adenosine deaminase deficiency as the first target disorder in gene therapy. Onodera M; Sakiyama Y Expert Opin Investig Drugs; 2000 Mar; 9(3):543-9. PubMed ID: 11060694 [TBL] [Abstract][Full Text] [Related]
11. Promising Results with Ex Vivo Lentiviral HSPC Gene Therapy in ADA-SCID. Am J Med Genet A; 2021 Aug; 185(8):2291-2292. PubMed ID: 34240545 [No Abstract] [Full Text] [Related]
12. Gene therapy for ADA-SCID, the first marketing approval of an Aiuti A; Roncarolo MG; Naldini L EMBO Mol Med; 2017 Jun; 9(6):737-740. PubMed ID: 28396566 [TBL] [Abstract][Full Text] [Related]
13. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID. Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494 [TBL] [Abstract][Full Text] [Related]
15. Gene therapy for adenosine deaminase deficiency. Cappelli B; Aiuti A Immunol Allergy Clin North Am; 2010 May; 30(2):249-60. PubMed ID: 20493400 [TBL] [Abstract][Full Text] [Related]
16. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992. Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of ADA gene expression and transduction efficiency in ADA/SCID patients undergoing gene therapy. Carlucci F; Tabucchi A; Aiuti A; Rosi F; Floccari F; Pagani R; Marinello E Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1245-8. PubMed ID: 15571238 [TBL] [Abstract][Full Text] [Related]
18. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug. Ferrua F; Aiuti A Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159 [TBL] [Abstract][Full Text] [Related]
19. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID. Taupin P IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313 [TBL] [Abstract][Full Text] [Related]
20. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials. Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]